Pivotal readout
TQ-B3139 keeps PFS lead over crizotinib in final ALK-positive lung cancer analysis
Final results from the 264-patient TQ-B3139-III-01 phase 3 study were published after about 46 months of follow-up. Investigator-assessed median progression-free survival was 30.4 months with TQ-B3139 versus 12.0 months with crizotinib as first treatment for advanced ALK-positive lung cancer. The drug has been approved in China for this setting since June 2024.
- Drugenvonalkib
- TargetAnaplastic lymphoma kinase receptor tyrosine kinase
- TargetProto-oncogene tyrosine-protein kinase ROS
- TrialNCT04009317
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.